Relmada Therapeutics, Inc. (NASDAQ:RLMD) Q4 2023 Earnings Call Transcript
Relmada Therapeutics, Inc. beats earnings expectations. Reported EPS is $-0.84, expectations were $-0.88.
Relmada Therapeutics Inc. (RLMD)
Market is closed
Sector: Pharmaceutical Preparations
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Deep Track Capital David Kroin | 2,044,507 | $8,464,259 | -28% | 0.28% |
| 2. | Opaleye Management James A. Silverman | 877,000 | $3,630,780 | +2824% | 0.96% |
| 3. | Palo Alto Investors William Leland Edwards | 732,400 | $3,032,136 | 0.27% | |
| 4. | Citadel Investment Group Ken Griffin | 375,658 | $1,555,224 | -14% | 0% |
| 5. | Two Sigma Advisors John Overdeck And David Siegel | 328,300 | $1,359,162 | +100% | 0% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Relationship | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $4.00 | 27,460 | Officer, Director | 244,024 | 2024-01-31 | Filing | |
| $3.90 | 40,999 | Officer, Director | 216,564 | 2024-01-30 | Filing | |
| $3.71 | 31,541 | Officer, Director | 175,565 | 2024-01-29 | Filing | |
| $4.06 | 6,875 | Officer | 34,903 | 2024-01-31 | Filing | |
| $3.89 | 15,000 | Officer | 28,028 | 2024-01-30 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Relationship | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $18.32 | 4,068 | Officer, Director | 88,774 | 2022-07-01 | Filing | |
| $18.45 | 8,848 | Officer, Director | 92,842 | 2022-07-01 | Filing | |
| $18.48 | 839 | Officer, Director | 101,690 | 2022-07-01 | Filing | |
| $19.01 | 10,698 | Officer, Director | 88,774 | 2022-06-30 | Filing | |
| $19.37 | 5,314 | Officer, Director | 99,472 | 2022-06-30 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 1,310,805 | $5,426,732 | 0% | |
| 2. | 949,841 | $3,932,342 | 0.28% | |
| 3. | 572,743 | $2,371,157 | 0% | |
| 4. | 302,744 | $1,253,360 | 0% | |
| 5. | 270,396 | $1,119,439 | 0% |
News See All
11 Best Psychedelic Stocks to Buy in 2024
Unlike substances like marijuana or cocaine, psychedelics are potent and serve as a form of gateway to an 'alternate reality' for those who use them.
5 Most Promising Psychedelic Stocks According to Hedge Funds
In this piece, we will take a look at the five most promising psychedelic stocks according to hedge funds.
Relmada Therapeutics, Inc. (NASDAQ:RLMD) Q3 2023 Earnings Call Transcript
Operator: Good afternoon, ladies and gentlemen. And welcome to Relmada Therapeutics, Inc. Third Quarter 2023 Earnings Conference Call. At this time, all lines are in listen-only mode.
Relmada Therapeutics, Inc. (NASDAQ:RLMD) Q2 2023 Earnings Call Transcript
Operator: Greetings, and welcome to Relmada Therapeutics Inc. Second Quarter 2023 Earnings Conference Call. [Operator Instructions] As a reminder, this conference is being recorded.
Relmada Therapeutics, Inc. (NASDAQ:RLMD) Q1 2023 Earnings Call Transcript
Operator: Good afternoon. Thank you for attending today's Relmada Therapeutics Inc. First Quarter 2023 Earnings Call. My name is Forum , and I will be your moderator for today's call.
Relmada Therapeutics, Inc. (NASDAQ:RLMD) Q4 2022 Earnings Call Transcript
Operator: Greetings and welcome to Relmada Therapeutics Fourth Quarter and Full Year 2022 Earnings Conference Call. As a reminder, this conference is being recorded.
5 Best Psychedelic Stocks to Buy According to Hedge Funds
In this article, we discuss 5 best psychedelic stocks to buy according to hedge funds.
10 Most Promising Psychedelic Stocks According To Analysts
In this article, we discuss 10 most promising psychedelic stocks according to analysts.
Relmada Therapeutics, Inc. (NASDAQ:RLMD) Q3 2022 Earnings Call Transcript
Operator: Good afternoon. My name is Kathy, and I'll be your conference operator for today. At this time, I would like to welcome everyone to the Relmada Therapeutics, Inc.
Billionaire Hedge Funds
